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ABSTRACT 
Adolescent cannabis use has grown because of increased availability and higher 
societal acceptance.  This increase in cannabis use is problematic as 
adolescents who experiment with cannabis are more likely to abuse cannabis 
and experiment with other illicit drugs such as cocaine.  The reason for the 
greater susceptibility to drugs use is unclear and may be the result of altered 
drug sensitivity after cannabis exposure.  Thus, the present investigation used 
the behavioral sensitization paradigm to examine the behavioral response of 
early adolescent rats to the cannabinoid agonist CP 55,940 (CP) or cocaine after 
repeated cannabinoid administration.  It was hypothesized that: (1) CP would 
cause a sensitized response in both male and female adolescent rats, (2) female 
rats would have a greater behavioral response than male rats, (3)  pretreatment 
with CP would induce cross-sensitization to cocaine, (4) pretreatment with 
cocaine would cause behavioral sensitization and conditioned activity in male 
and female adolescent rats.  In the first experiment, 137 male and female 
Sprague-Dawley rats were given CP (4, 13.2, or 40 µg/kg, IP) or vehicle (50% 
DMSO/H2O) once daily for 5 consecutive days on postnatal day (PD) 30- PD 34.  
Distance traveled and stereotyped movement was assessed for 1 h after each 
drug injection. After a 48 h abstinence period (i.e., on PD 36), rats were given CP 
(4 or 13.2 µg/kg, IP) and distance traveled and stereotyped movement was 
monitored for 2 h.  In the second experiment, 146 male and female rats were 
tested with the same protocol as in Experiment 1 except that rats were given CP 
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(13.2 or 4 µg/kg), cocaine (20 mg/kg), or vehicle (saline or 50% DMSO/H2O) for 
five days and then tested with saline or cocaine (10 mg/kg) after 48 h.  In the first 
experiment, no dose of CP altered distance traveled scores or stereotyped 
movement over the five pre-exposure days nor did CP cause behavioral 
sensitization on the test day.  In the second experiment, pretreatment with 
cocaine led to enhanced distance traveled scores and stereotyped movement 
when challenged with cocaine (behavioral sensitization) or saline (conditioned 
activity) on test day.  In contrast, CP-pretreated rats did not show greater activity 
when injected with cocaine or saline on test day.  These data show that 
cannabinoids do not act like psychostimulant drugs, since CP did not cause the 
same changes in drug sensitivity as cocaine.  The cocaine sensitization observed 
in adolescent rats indicates that this age group is particularly vulnerable to the 
rewarding effects of cocaine, and suggests that early cocaine exposure can 
augment drug seeking behavior.  The failure to detect cannabinoid-induced 
sensitization, conditioned activity, or cocaine cross-sensitization during 
adolescence suggests that CP, when given at a consistent dose, does not 
increase the addictive properties of cannabinoids or cocaine.  The results also 
indicate that cannabinoid use does not alter drug responsivity or lead to greater 
drug seeking and abuse in the adolescent population. 
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CHAPTER ONE 
INTRODUCTION 
Cannabis 
Cannabis has been called by several names including hemp, hashish, 
ganja, and marijuana (Russo, 2007).  The cannabis plant has been used for 
clothing, paper, rope, and as a medicine throughout many time periods in various 
cultures. Emperor Shen Neug of China in 2,000 B.C. was the first to record 
cannabis use, or ‘ma’ as a textile and for soil fertilization (Zuardi, 2006). Hemp 
rope was also used by the Vikings for both coarse textiles and fine household 
textiles (Skoglund, Nockert & Holst, 2013).  This plant has also been used in 
religious and spiritual rituals for enlightenment and communication with spirits 
(Bapat, 2015; Russo, 2007; Touw, 1981; Zuardi, 2006).  The Materia Medica 
Sutra (Pen ts’ao Ching) first documented the psychotropic properties of cannabis 
sativa L. (Huo ma ren) and refers to the “fruit of the cannabis” which if taken 
would cause the user to have visions of spirits and devils (Zuardi, 2006).  
Throughout history, various cultures and religions have noted that cannabis may 
have useful properties (Aldrich, 1997). 
The Chinese were also the first to document the medical uses of cannabis 
for pain reduction, female reproductive health, and constipation relief (Touw, 
1981; Zuardi, 2006).  Common medical uses for cannabis that have been 
reported by cultures throughout Asia and the Middle East include analgesia, 
appetite stimulation, diarrhea relief, and mental relaxation (Bapat, 2015; Russo, 
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2007; Touw, 1981; Zuardi, 2006).  However, cannabis also produces euphoric 
and psychoactive effects that have influenced cultures to outlaw its use.  For 
example, the Chinese called the resinous seeds (Ma Fen) poisonous and made it 
illegal to consume them (Li, 1978; Russo, 2007; Touw, 1981; Zuardi, 2006).  
Furthermore, India prohibited cannabis resin (haras) despite cannabis (bhang) 
being considered one of the five sacred plants of India (Bapat, 2015; Russo, 
2007; Touw, 1981; Zuardi, 2006).  
The United States also has a long history with cannabis. In 1916 botanists 
Lyster H. Dewey and Jason L. Merrill of the Department of Agriculture reported 
that hemp would make a more efficient and environmentally safer paper 
compound compared to wood (Dewey & Merrill, 1916, pg. 25).  However, the 
prohibition of marijuana had already begun in California in 1915. In 1937, the 
United States Congress passed the Marijuana Tax Act which made anyone 
selling marijuana pay an occupational tax and register with the Internal Revenue 
Service (McKenna, 2014; Musto, 1972).  This act passed with the help of 
negative propaganda like the film “Reefer Madness” (Stringer & Maggard, 2016).  
Interestingly, Harry Anslinger and the Federal Bureau of Narcotics passed the 
Marijuana Tax act essentially outlawing cannabis in 1937, the same year Dr. 
William C. Woodward of The American Medical Association proposed the study 
of cannabis for medical use (McKenna, 2014; Newton, 2014). 
The Controlled Substance Act was then passed in 1970 and banned the 
medical and recreational use of marijuana by placing it on the Schedule I drug 
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list, the most restrictive drug schedule.  Drugs that are on this schedule are 
defined as drugs with no currently accepted medical use and a high potential for 
abuse. Nevertheless, in 1992, the first pharmaceutical based cannabis 
compound, dronabinol, became legal for medical use specifically for AIDS-
wasting syndrome (Werner, 2001).  In 1996, California became the first of 25 
states to decriminalize medical marijuana for persons in California suffering from 
cancer, glaucoma, migraines, seizures, severe nausea, muscle spasms, and 
chronic pain.  In 2012, Colorado and Washington decriminalized cannabis 
recreationally for people over the age of 21, and Alaska and Oregon followed suit 
in 2014.  Most recently, California has passed laws for recreational use beginning 
in 2017.  Despite these changes in state law, the federal government still 
considers cannabis an illicit substance and it remains listed as a Schedule I drug.  
Cannabis Plant 
The cannabis plant grows indigenously in many regions, in Asia and the 
Middle East.  The two main species of the cannabis plant are indica and sativa.  
In addition, a number of genetic hybrids have been created through cross 
breeding of indica and sativa plants (Russo, 2007).  The indica strain of the plant 
grows short and stocky with dark leaves while the sativa strain grows tall and thin 
with light leaves (Russo, 2007).  Different types of sativa and indica strains have 
been shown to produce differing effects and are now being classified by their 
genetic makeup and reported medical benefits (Janatová et al., 2018).  Cannabis 
indica has been reported to have pain relieving effects on the body, produce 
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sedation, and help with nausea and lack of appetite (Pearce, Mitsouras & Irizarry, 
2014).  The sativa strains, on the other hand, are self-reported to cause euphoric 
and psychedelic effects and are considered energizing and stimulating (Pearce 
et al., 2014).  
There are three main preparations of the cannabis plant including the 
cannabis resin (hash), the seeded plant that contains stems, flowers, and leaves, 
and the unfertilized female flowers which are most commonly used to produce 
psychoactive effects (Russo, 2007).  The cannabis flowers contain numerous 
active chemical compounds known as cannabinoids, which are responsible for 
the altered state that is experienced by someone who uses the cannabis plant.  
The two main cannabinoids of this plant, (−)-trans-Δ9-tetrahydrocannabinol 
(THC) and cannabidiol (CBD), are believed to mediate most cannabis-induced 
effects (Russo, 2007).  
When used acutely, cannabis can cause red eyes, sleepiness, decreased 
motor coordination, and slow respiratory rate (Grotenhermen, 2004).  The 
psychological effects observed with acute cannabis use include dysphoria, 
alterations to attention, concentration, and learning, and somatic and visual 
sensations (Grotenhermen, 2004).  Although the acute effects are well 
understood, the persistent long-term effects of cannabis use are variable and 
depend on age of onset and duration of use.  Overall, decreases in verbal 
fluency, visual attention, and executive functioning have been associated with 
cannabis use that is initiated before the age of 15 (Fontes et al., 2011).  
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Conversely, onset of cannabis use after the age of 15 does not produce the 
same long-term consequences.  Cannabis withdrawal is common in adults but 
people do not commonly seek treatment for these symptoms.  Cannabis 
withdrawal can include irritability, difficulty sleeping, restlessness, and changes in 
mood such as depression and nervousness  (Gorelick et al., 2012; Verweij et al., 
2013).  In sum, the cannabis plant contains cannabinoids that can acutely 
produce desirable effects but can also have long-term consequence, especially if 
the onset of use begins at an early age.  
Challenges of Cannabis Legalization 
Even though cannabis is still illegal according to the United States federal 
government, the decriminalization of cannabis by several states has led to the 
development of numerous marketable products with varying levels of potencies 
(ElSohly et al., 2016).  Today the cannabis flowers sold in recreational cannabis 
shops can contain THC levels averaging around 20% compared to an average of 
about 4% in 1995 (Elsohly et al., 2016).  This increase in potency means that 
current THC effects are no longer comparable to those observed in earlier 
research and, thus, the effects of this level of potency are not well understood 
(Vergara et al., 2017).  Furthermore, concentrated waxes that can contain up to 
100% THC have been popularized recently (Loflin & Earlywine, 2014).  These 
concentrated waxes known as “dabs” are self-reported to cause increased 
tolerance and withdrawal to THC (Loflin & Earlywine, 2014).  Cannabis is also 
processed into oils and butters that are turned into candies, drinks, condiments, 
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and other daily food items, which has led to unforeseen issues.  For example, 
with no federal regulations to control access to these poorly labeled cannabis 
products there has been an increase in accidental exposure in young children 
(Davis et al., 2016; Wang et al., 2014). 
Cannabis has become the most commonly used illicit substance in the 
United States (Johnston et al., 2018).  The changes in the legalization of 
cannabis, especially in states supporting cannabis, has led to an increase in 
reports of cannabis dependence and abuse (Cerdá, Wall, Keyes, Galea & Hasin, 
2012). Cannabis use disorder is characterized by the following criteria; the use of 
cannabis for over 1 year, uncontrolled craving and consumption that are related 
to the user having difficulty controlling use, difficulty quitting use, or significantly 
impairing daily life functioning (American Psychological Association, 2013).  
Although cannabis use disorder is seen at lower rates than other disorders 
involving illicit substances, its prevalence is increasing primarily among the 
young adult population (Haberstick et al., 2014; Peer et al., 2013).  Late 
adolescence and early adulthood populations are at the highest risk of cannabis 
use disorder, with the most susceptible age of onset ranging from 14-24 years of 
age (Farmer et al., 2015).  In fact, patients with a lifetime diagnosis of cannabis 
use disorder report that their first episode of cannabis dependence was under the 
age of 18 (Farmer et al., 2015)  As a result, this young population is vulnerable to 
cannabis use disorder, thus, making the consequences of adolescent cannabis 
use an issue of public health concern (Haberstick et al., 2014).  
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CHAPTER TWO 
THE ENDOCANNABINOID SYSTEM: 
 RECEPTORS 
After the primary psychoactive component of cannabis, THC, was 
identified, it was quickly discovered that this compound works by binding to 
distinct receptors in the central and peripheral nervous systems.  These 
receptors were labelled cannabinoid receptors, which includes the cannabinoid 
one (CB1) and cannabinoid two (CB2) receptors (For review; see Howlett et al., 
2002).  Endogenous ligands were eventually found to bind to these receptors, the 
two endogenous cannabinoid ligands are anandamide and 2-
arachidonoylglycerol (2-AG; Bisogno et al., 1999; Felder et al., 1996).  Together, 
the receptors and the endogenous ligands are known to be important 
neuromodulators of neuronal activity. In particular, the endocannabinoid system 
is important for the modulation of pain, feeding, neuroprotection, and reward (For 
review; see Howlett et al., 2002).  
Cannabinoid Receptors 
CB receptors have been characterized across human, porcine, primate, 
and rodent brains (For review; see Howlett et al., 2002).  Until recently, CB1 
receptors were thought to only exist in the central nervous system whereas CB2 
receptors were confined to the peripheral nervous system.  Now it is known that 
both receptors are distributed throughout the brain and body (Gong et al., 2006).  
CB receptors are composed of seven hydrophobic segments that consist of N-
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terminal extracellular and C-terminal intracellular domains (For reviews; see 
Howlett et al., 2002; Pertwee, 1997; Svíženská, Dubový & Šulcová, 2008).  The 
CB1 receptor has been extensively studied but the CB2 receptor is not as well 
understood.  Additionally, there has been discussion of a third CB receptor, the 
vanilloid receptor (TRPV1 or VR1), with similar neurological functions and 
expression as the endocannabinoid system (Cristino et al., 2006).  
Adult Distribution and Density  
CB1 receptors are expressed in adult rats on the terminal axonal fibers of 
neurons, specifically on presynaptic terminals (Howlett et al., 2002).  CB1 
receptors are located throughout the limbic system, are involved in the formation 
of memories and play an important role in behavior and cognition (Egertová & 
Elphick, 2000; Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992; 
Rajmohan & Mohandas, 2007).  Overall, the hippocampal formation has more 
dense binding than other areas of the brain (Herkenham et al., 1991; Mailleux & 
Vanderhaeghen, 1992).  The densest binding is found in the molecular layer of 
the dentate gyrus and the CA1 and CA3 regions of Ammons horn (Egertová & 
Elphick, 2000; Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992).  In 
contrast, binding in the granule cell layer of the dentate gyrus is scarce 
(Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992).  Similarly, the 
septum and amygdala exhibit sparse binding (Herkenham et al., 1991, Mailleux & 
Vanderhaeghen, 1992).  
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In adult rats, the second densest site of CB1 receptors is the basal 
ganglia, which controls movement, coordination, and procedural learning 
(Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992).  Specifically, within 
the basal ganglia the highest densities of CB1 receptors are found in the globus 
pallidus, entopeduncular nucleus, and substantia nigra pars reticulata (Egertová 
& Elphick, 2000; Herkenham et al., 1991, Mailleux & Vanderhaeghen, 1992; 
Matsuda, Bonner & Lolait, 1993; Tsou, Brown, Sanudo-Pena, Mackie & Walker, 
1998).  These areas of the basal ganglia show a gradient of binding intensity that 
increases from the medial to the lateral regions (Egertová  & Elphick, 2000).  In 
the striatum, the dorsolateral region has denser binding than the ventromedial 
area, while the nucleus accumbens has moderate to low densities of CB1 
receptors (Herkenham et al., 1991; Mailleux & Vanderhaeghen, 1992).  The 
basal ganglia also has CB1 receptors in white matter tracts.  Specifically, the 
striatonigral descending pathway contains detectable CB receptors (Herkenham 
et al., 1991).  
The density of CB1 receptors in the cerebral cortex, the portion of the 
brain that controls higher level functioning, displays a two-layer pattern.  
Receptor autoradiography shows high densities in layers I and IV and lower 
densities in layers II and III (Herkenham et al., 1991; Mailleux & Vanderhaeghen, 
1992).  The hindbrain has low staining in the pons and medulla but intense 
staining in the cerebellum (Matsuda et al., 1993).  Within the cerebellum, which is 
involved in motor coordination and movement, very dense CB1 binding can be 
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identified throughout the molecular layer of the cerebellar cortex, but sparse 
labeling occurs in the cerebellar granular layer (Herkenham et al., 1991; Mailleux 
& Vanderhaeghen, 1992).  Furthermore, low densities of CB1 binding occur in 
the corpus callosum, thalamus, hypothalamus, and midbrain (Egertová & Elphick, 
2000; Matsuda et al., 1993; Tsou et al., 1998). 
Despite earlier reports that CB2 receptors were only found in the 
peripheral nervous system, the CB2 receptor has been discovered in brain areas 
including the orbital, visual, motor, and auditory cortices (Gong et al., 2006).  
Furthermore, CB2 receptors are found in the anterior olfactory nucleus and the 
pyramidal neurons of the hippocampus, specifically, the CA2 and CA3 regions.  
In addition, CB2 receptor staining was found in the thalamus, periaqueductal 
gray, substantia nigra pars reticulata, midbrain and medulla.  There is also 
intense staining of the Purkinje cell bodies and moderate staining of their 
dendrites in the cerebellum (Gong et al., 2006).  Thus, CB2 receptors are found 
in similar locations as the CB1 receptors; however, their distribution patterns and 
densities within these regions differ (Gong et al., 2006).  
Gestational Development  
There are similarities and differences between the gestational CB receptor 
system and the adult CB receptor system.  The expression of CB1 receptor 
mRNA has been measured in rats as early as gestational day (GD) 14 
(Berrendero et al., 1998).  Specific binding at GD 18 is detected in areas such as 
the hippocampus, cerebral cortex, and cerebellum, which is similar to adults 
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(Berrendero et al., 1998).  CB1 receptor mRNA is detectable in the dentate gyrus 
of the hippocampus by GD 16 and is localized in the subfields of the Ammon’s 
horn by GD 21.  CB1 receptor mRNA progressively increases in the cerebral 
cortex from GD 16 to GD 21. By GD 21, CB1 receptor binding can be identified in 
the basal ganglia, hippocampus, cerebral cortex, and cerebellum (Berrendero et 
al., 1999).  Interestingly, CB1 mRNA was measurable in the midbrain, pons, and 
brainstem from GD 16 to GD 21 whereas these brain regions do not contain 
cannabinoid receptors in adulthood (Berrendero et al., 1998; Herkenham et al., 
1991; Mailleux & Vanderhaeghen, 1992).  The distribution of CB1 receptors 
found in the corpus callosum, anterior commissure, fornix, fimbria, fasciculus 
retroflexum, and the stria medullaris and terminalis are also inconsistent with the 
distribution of CB1 receptors in adulthood (Berrendero et al., 1998; 1999; 
Romero et al., 1997). 
Postnatal Development  
The distribution of CB1 receptors in early postnatal development is 
consistent with the adult neuronal localization of CB1 receptors (Belue, Howlett, 
Westlake & Hutchings, 1995).  The densities of CB1 receptors in the basal 
ganglia and limbic system steadily increase from PD 5 to adulthood (Berrendero 
et al., 1999).  On the other hand, binding levels in the caudate putamen, septum 
nuclei, and nucleus accumbens appear to first decrease from GD 21 until birth, 
before they begin to increase postnatally (Belue et al., 1995; Berrendero et al., 
1999).  The striatal levels of CB1 receptors double from PD 0 to PD 7 and then 
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double again by PD 21 before reaching adult levels (Belue et al., 1995; 
Berrendero et al., 1999).  CB1 receptors located on external (II-III) and internal 
(V-VI) layers of the cerebral cortex continue to increase at a consistent rate from 
PD 21 until reaching adult levels (Berrendero et al., 1998; Berrendero et al., 
1999; Herkenham et al., 1991; Mailleux & Vanderhaeghen, 1992).  
An increase in CB1 receptor levels across development is also observed 
with receptor binding in the cerebellum and cortex, except that CB1 binding in the 
cortex increases less from PD 14 to adulthood than in the striatum and 
cerebellum (Belue et al., 1995).  CB1 receptors in the hippocampus display a 
gradual increase throughout development before reaching adult levels (Belue et 
al., 1995).  Lastly, the densities of CB1 receptors found in white matter areas, 
such as the corpus callosum and sub-ventricular zone of the neocortex, during 
gestational development, are no longer visible during postnatal development and 
in adulthood (Berrendero et al., 1998; Berrendero et al., 1999; Romero et al., 
1997). 
Cellular Signal Transduction 
Stimulation of both CB1 and CB2 receptors causes the activation of 
cellular signal transduction through Gi/o protein pathways (For reviews; see 
Howlett, 2002; Pertwee, 1997).  These receptors, when activated, cause the 
inhibition of cyclic AMP formation.  Through this inhibition, CB receptors 
modulate intracellular cyclic AMP, which regulates ion channels via protein 
kinase A (for reviews; see Howlett, 2002; Pertwee, 1997).  CB receptors are 
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coupled to inwardly rectifying potassium channels. Through the Gi/o protein 
pathway, CB receptors inhibit voltage-gated calcium channels which increases 
intracellular calcium (For reviews; see Howlett, 2002; Pertwee, 1997).  CB 
receptors also stimulate the phosphorylation of mitogen-activated protein kinase.  
Lastly, CB1 and CB2 receptors facilitate immediate early gene expression and, 
regulate protein synthesis (For reviews; see Howlett, 2002; Pertwee, 1997).  
Cannabinoid Receptors and Neurotransmission 
Activation of CB1 receptors on the presynaptic terminals inhibits the 
release of both excitatory and inhibitory neurotransmitters (For review; see 
Howlett et al., 2002).  CB1 receptors are heavily involved in GABAergic inhibition 
in the globus pallidus, substantia nigra and hippocampus (Maneuf, Crossman, & 
Brotchie, 1996; Maneuf, Nash, Crossman & Brotchie, 1996; Hoffman & Lupica, 
2000; Romero, De Miguel, Ramos & Fernández-Ruiz, 1997).  Furthermore, 
activation of cannabinoid receptors can also increase the release of other 
transmitters.  For example, dopamine release is stimulated in the nucleus 
accumbens, ventral tegmental area, and substantia nigra by the activation of 
CB1 receptors (Oleson & Cheer, 2012).  In addition, when presynaptic CB1 
receptors are activated there are increases in acetylcholine in the hippocampus 
(Acquas, Pisanu, Marrocu & Di Chiara, 2000) and glutamate release in the 
cerebral cortex (Ferraro et al., 2001).  Overall, CB1 receptors modulate synaptic 
transmission across the brain (Kreitzer, 2005).  
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CHAPTER THREE 
THE ENDOCANNABINOID SYSTEM: 
 ENDOGENOUS CANNABINOIDS 
 Once CB receptors were discovered, it was apparent that there were 
endogenous ligands that must bind to these receptors.  Anandamide was 
identified first and named after the Sanskrit word for bliss because its effects 
were similar to THC (Devane et al., 1992). Next, 2-AG was identified and was 
found to be more abundant in the brain than anandamide (Stella, Schweitzer & 
Piomelli, 1997).  These two endocannabinoids are responsible for the stimulation 
of CB receptors and the neuromodulatory actions of the endocannabinoid system 
(For review, see Howlett, 2002). 
Anandamide 
Distribution 
  The distribution of anandamide in the brain coincides with the known 
distribution of cannabinoid receptors (Bisogno et al., 1999; Felder et al., 1996).  
Thus, rats have the highest levels of anandamide in the hippocampus, brainstem, 
medulla, and striatum (Bisogno et al., 1999; Felder et al., 1996); whereas, low 
levels of anandamide are found in the cerebellum, thalamus, diencephalon, and 
cortex (Bisogno et al., 1999; Felder et al., 1996).  The precursor for anandamide, 
N-arachidonoyl phosphatidylethanolamine (NArPE), is also measured in high 
concentrations in the brainstem, striatum, and hippocampus while low 
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concentrations occur in the cerebellum.  The levels of NArPE are much greater 
than anandamide (Bisogno et al., 1999).   
Synthesis and Release 
Anandamide is created from free arachidonic acid and ethanolamine 
(Sugiura et al., 1996).  Anandamide is produced on demand and its biosynthesis 
is controlled by intracellular calcium levels that activate phospholipase D and 
catalyze NArPE hydrolysis (For review, see Basavarajappa, 2007, Cadas, Di 
Tomaso & Piomelli, 1997; Di Marzo et al., 1994).  NArPE activates N-
acyltransferase (NAT), which causes the movement of an acyl group from 
phospahatidylcholine to the ethanolamine portion of phosphatidylethanolamine, 
thus producing N-acyl phosphatidylethanolamine (NAPE; Basavarajappa, 2007; 
Cadas et al., 1997; Di Marzo et al., 1994,).  Anandamide and phosphatic acid are 
then released into the synaptic cleft after cleavage by NAPE specific 
phospholipase D (For review, see Basavarajappa, 2007).  It is unclear if the rate 
limiting step is the cleavage by NAPE-specific phospholipase D or the activation 
of NAT (Hansen, Hansen, Schousboe & Hansen, 2000; Maccarrone et al., 1998). 
Metabolism  
  After the release of anandamide into the extracellular space, it 
experiences selective and rapid uptake through the anandamide membrane 
transporter (Deutsch et al., 2001).  After anandamide is removed, intracellular 
degradation occurs by enzymatic hydrolysis (Deutsch & Chin, 1993; Di Marzo et 
al., 1994).  The enzyme that causes anandamide hydrolysis, fatty acid amide 
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hydrolase (FAAH), is properly known as arachidonoylethanolamide 
amidohydrolase (Deutsch et al., 2001; Maccarrone & Finazzi-Agró, 2002).  The 
metabolism of anandamide occurs when FAAH breaks the amide bond, which 
causes the release of arachidonic acid and ethanolamine (Deutsch et al., 2001; 
Maccarrone & Finazzi-Agró, 2002).  
Behavioral Effects 
Anandamide can cause a wide range of behavioral effects.  In rats, it 
increases in the motivation to eat, frequency of eating, and food intake as well as 
reduced eating latency are observed after injections of anandamide (Martıńez-
González et al., 2004; Williams & Kirkham, 2002).  Sexual behavior also changes 
when rats are given injections of anandamide.  Specifically, the frequency of 
ejaculation changes in a dose-dependent manner with a low dose decreasing 
ejaculations and a high dose increasing ejaculation.  Anandamide also reduces 
pain in the formalin test (Guindon, De Léan, & Beauliue, 2006).  In addition, 
anandamide modulates sleep wake cycles by causing rapid eye movement and 
slow-wave sleep II, which regulates alertness in rats (Murillo-Rodriguez et al., 
1998).  Furthermore, anandamide and the exogenous cannabinoid THC affect 
open field behavior similarly because both THC and anandamide decrease 
grooming, rearing, and motor behavior while increasing periods of inactivity 
(Romero et al., 1995).   
Interestingly, both non-human primates and rats will intravenously self-
administer anandamide (Justinova, Solinas, Tanda, Redhi & Goldberg, 2005; 
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Solinas, Justinova, Goldberg & Tanda, 2005).  This self-administration behavior 
is accompanied by an elevation of dopamine levels in the accumbens shell and 
suggests that anandamide may have rewarding properties (Solinas et al., 2006).  
Additionally, anandamide modulates the release of other neurotransmitters.  For 
example, anandamide decreases serotonin in the hippocampus and increase it in 
the hypothalamus (Hao, Avraham, Mechoulam & Berry, 2000).  Anandamide also 
increases dopamine in the hippocampus and hypothalamus as well as increases 
cortisol levels (Hao et al., 2000).  Overall, anandamide modulates hunger, sexual 
activity, alertness, and neurotransmission and, like THC, produces rewarding 
effects (Guindon et al., 2006; Hao et al, 2000; Justinova et al., 2005; Kirkham & 
Williams, 2001; Martıńez-González et al., 2004; Romero et al., 1995; Solinas et 
al., 2006;). 
2-Arachidonoylglycerol 
Distribution 
Distribution of 2-AG has the highest levels in the brainstem and 
hippocampus and moderate to high levels in the limbic forebrain and striatum 
(Bisogno et al., 1999).  The lowest levels of 2-AG are found in the hypothalamus, 
cerebellum, and anterior pituitary (Bisogno et al., 1999; Sugiura & Waku, 2000).  
Interestingly, 2-AG levels are found to fluctuate with the light/ dark cycle in rats 
(Valenti et al., 2004). 
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Synthesis and Release 
The biosynthetic pathways of 2-AG include a few possible routes (For 
review, see Basavarajappa, 2007).  The first pathway is mediated by 
phospholipase C hydrolysis to produce diacylglycerol which, in turn, is converted 
into 2-AG by diacylglycerol lipase (Sugiura et al., 1995).  The second possible 2-
AG biosynthesis route is through the hydrolysis of phosphatidylinositol from 
phosphatidylinositol-specific phospholipase A1, which is converted into 2-AG by 
lyso-phosphatidylinositol specific phospholipase C (Sugiura et al., 1995).  
Therefore, it is clear that phospholipase C and diacylglycerol lipase are important 
for 2-AG synthesis but it is unclear the main biosynthetic pathway. 
Inactivation and Metabolism  
The inactivation of 2-AG occurs by reuptake through the anandamide 
membrane transporter and is then metabolized into 2-arachidonyl LPA by 
monoacyl glycerol kinase, which is then converted into 1-stearoyl-2 arachidonoyl 
PA (For review, see Basavarajappa, 2007).  
Behavioral effects 
Multiple behavioral and neurological functions are modulated by 2-AG.  
Elevated levels of 2-AG have been found after head injury and this elevation may 
help to reduce brain edema and hippocampal cell death and improve the level of 
recovery (Panikashvili et al., 2001).  2-AG serves as the immediate response to 
reduce inflammation (Berdyshev, Schmid, Krebsbach & Schmid, 2001) and 2-AG 
inhibits invasive prostate cancer cells (Nithipatikom et al., 2004). Furthermore, 2-
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AG is involved in stress-related behaviors.  For example, the formation of 2-AG is 
triggered by stress and helps enhance stress-induced analgesia (Hohman et al., 
2005).  2-AG levels are also elevated after chronic stress exposure suggesting a 
role in preventing the development of anxiety (Sumislawski, Ramikie, & Patel, 
2011).  
2-AG has been linked to the rewarding properties of stimuli such as food 
and drugs.  Mice given high fat diets show an increase in hypothalamic 2-AG, 
which may increase the rewarding and reinforcing effects of the high fat diet 
(Higuchi et al., 2012).  Squirrel monkeys self-administer 2-AG, which shows that 
it has reinforcing properties like drugs of abuse (Justinova, Yasar, Godfrey, 
Redhi & Goldberg, 2011).  Overall, 2-AG is a neuroprotectant and cancer growth 
inhibitor, it has anti-inflammatory and analgesic properties, reduces stress, and 
augments reward circuitry (Berdyshev et al., 2001; Higuchi et al., 2012; Hohman 
et al., 2005; Justinova et al., 2011; Nithipatikom et al., 2004; Panikashvili et al., 
2001; Sumislawski et al., 2011; Vigano et al., 2003). 
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CHAPTER FOUR 
EXOGENOUS CANNABINOIDS  
The cannabis plant includes over 70 chemicals that are responsible for the 
psychoactive and medical properties experienced by the user (ElSohly & Slade, 
2005).  The actions of the chemical constituents in cannabis have been mimicked 
and inhibited with synthetic compounds that can bind to CB1 and CB2 receptors 
(Pertwee et al., 2010).  Both plant and synthetic cannabinoids have allowed for a 
more in-depth examination of the behavioral outcomes associated with CB 
receptors and have given insight into the appeal of cannabis use recreationally 
and medically.  
Tetrahydrocannabinol 
THC is the most commonly studied exogenous cannabinoid and produces 
a wide range of actions.  The psychological aspects of THC can be separated 
into four categories: affective (euphoria), sensory (increased perception of 
stimuli), somatic (body sensations), and cognitive (problems with concentration, 
perception and time estimation; Perez-Reyes, 1999).  The psychological and 
physiological effects of THC have been thoroughly assessed. This cannabinoid 
can influence cognition by altering perception and psychomotor performance as 
well as regulate emotional states (For review, see Grotenhermen, 2007).  
Futhermore, THC modulates functions of the nervous system, cardiovascular 
system, hormonal system, immune system and respiratory system (For review, 
see Grotenhermen, 2007) 
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THC can be absorbed into the body via multiple routes of administration.  
Inhalation is the most common way THC enters the human body (Agurell et al., 
1986).  The bioavailability of inhaled THC ranges from 2-56% because there is 
variability in the frequency and quantity of THC use depending on the individual.  
After smoke inhalation, the blood plasma levels of THC peak quickly within 
anywhere from 3 to 10 min (Huestis, 2005).  In contrast, the oral administration of 
THC has a much slower onset of effects and more erratic effects compared to 
inhalation (Law, Mason, Moffat, Gleadle & King, 1984).  The bioavailability of 
THC taken orally is about 10-20% after it is absorbed into the gastrointestinal 
tract and liver (Wall, Sadler, Brine, Taylor & Perez-Reyes, 1983).  When 
ingested, the effects of THC peak between 60 and 120 minutes and last an 
average of 4-6 hr (Ohlsson et al., 1982).  
As shown in rats, once absorbed into the body, THC binds to lipoproteins 
and 90% of THC is found in blood plasma and 10% is found in red blood cells 
(Fehr & Kalant, 1974).  THC is primarily metabolized by cytochrome P450, with 
over 80 different metabolites produced (Huestis, 2005; Sharma, Murthy & 
Bharath, 2012).  At low doses (16 mg), THC is eliminated from plasma within 3 to 
6 hours whereas high doses (34 mg) can take 6-27 hr (Huestis, 2005).  The half-
life of THC is 25-26 hr but in heavy users the half-life can range from 19-53 hr 
(Hunt & Jones, 1980; Wall, Sadler, Brine, Taylor & Perez‐Reyes, 1983).  Within 5 
days of use, up to 90% of THC has been eliminated from the body, over 65% is 
excreted in the fecal matter, and around 25% through urine (Huestis, 2005; Wall 
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et al., 1983).  Overall, a single dose of THC can be detected in the body for up to 
12 days, moderate use can be detected for around 30 days, and THC can be 
detected up to 77 days in heavy users (Ellis, Mann, Judson, Schramm & 
Tashchian, 1985).  A lethal human dose of cannabis has not been reported but 
an oral dose of 800-1900 mg/kg THC is lethal to rodents (Grotenhermen, 2007; 
Thompson, Rosenkrantz, Schaeppi & Braude, 1973).  
THC is a partial agonist of both CB1 and CB2 receptors, but with lower 
efficacy for the CB2 than CB1 receptor (Howlett et al., 2002; Pertwee, 2008).  
THC activates CB1 receptors located on presynaptic terminals in the central 
nervous system, thus modulating the release of neurotransmitters glutamate, 
GABA, dopamine and acetylcholine (Pertwee & Ross, 2002).  These 
neuromodulatory actions have been observed in the nucleus accumbens and 
synaptic projections that extend to the ventral tegmental area, hippocampus, and 
prefrontal cortex (Pertwee, 2008; Pertwee & Ross, 2002).  In sum, THC is a non-
lethal drug that takes an average of 30 days to be excreted from the body (Ellis 
et al., 1985).  This partial cannabinoid receptor agonist is involved in numerous 
behavioral and neurological processes that induce reward as well as medical 
value.  
Cannabidiol 
The plant cannabinoid, cannabidiol (CBD), does not produce the euphoric 
effects observed with THC but it can have a wide range of effects, including 
antipsychotic, antiepileptic, anxiolytic, and anti-inflammatory actions (Izzo, 
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Borrelli, Capasso, Di Marzo & Mechoulam, 2009).  Inhalation of CBD has an 
average bioavailability of 31% after a single use (Ohlsson et al., 1986).  CBD 
binds to CB1 and CB2 receptors where it acts as both an antagonist and inverse 
agonist (Pertwee, 2008; Thomas et al., 2007) and inhibits the effects of the 
synthetic cannabinoid agonists CP55940 and R-(+)-WIN 55,212 (Pertwee et al., 
2002).  CBD has therapeutic value for the treatment of symptoms associated with 
cancer, arthritis, anxiety, diabetes, and immune disorders (For review, see 
Mechoulam, Peters, Murillo-Rodriguez & Hanuš, 2007).  Overall, CBD has value 
as a medical treatment for a variety of ailments without the psychoactive side-
effects experienced with THC. 
Synthetic Cannabinoids 
Synthetic cannabinoids such as CP, HU-210, and R-(+)-WIN 55,212 bind 
to both CB1 and CB2 receptors and have been used to characterize the CB1 
receptor system (For review, see Howlett et al., 2002).  These synthetic CB 
receptor agonists have similar behavioral effects as THC and endogenous 
cannabinoids including hypothermia, analgesia, catalepsy, and locomotor 
suppression (Tai & Fantegrossi, 2014).  These agonists modulate 
neurotransmission by inhibiting GABA release in the substantia nigra and 
hippocampus whereas synthetic cannabinoids increase acetylcholine in the 
hippocampus, dopamine in the nucleus accumbens, and glutamate in the 
cerebral cortex (For review, see Howlett et al., 2002).  Overall, synthetic 
cannabinoid agonists have similar physiological and behavioral effects as THC. 
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CB antagonists, such as SR14716A, AM281, and LY320135, block the 
effects of the CB receptor system (Pertwee, 2005).  The antagonist AM281 can 
reduce food intake in rats, increase locomotor activity in mice, and increase 
glutamate release in the cerebellum (Pertwee, 2005).  In contrast, LY320135 
blocks the effects of CB receptor agonists and works as an inverse agonist in the 
CB1 signal transduction pathway (Howlett et al, 2002).  The most studied 
antagonist is SR14716A because this potent CB1 ligand is able to inhibit CB 
receptor agonists as well as reverse the effects of the CB1 and CB2 receptors 
(Howlett et al, 2002).  The behavioral effects that are observed with SR14716A 
include enhanced locomotor activity, hyperalgesia, and pro-inflammatory 
responses (Pertwee, 2005).  SR14716A increases the release of acetylcholine, 
epinephrine, and GABA in the hippocampus as well as increase glutamate in the 
prefrontal cortex and striatum (Pertwee, 2005).  Overall, these antagonists 
reverse the actions of the cannabinoid system.  
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CHAPTER FIVE 
BEHAVIORAL SENSITIZATION 
The prevalence of cannabis use disorder has led to the conclusion that 
cannabis has addictive properties (Hasin et al., 2015).  Therefore, it is important 
to have a better understanding of how cannabis alters behavior and leads to 
compulsive drug taking.  Animal models, including self-administration, drug 
discrimination, conditioned place preference, and behavioral sensitization, have 
been invaluable tools for studying the addictive properties of drugs such as 
cannabis (Maldonado & de Fonseca, 2002; Sanchis-Segura & Spanagel, 2006).  
In particular, behavioral sensitization examines incentive value or “craving” for a 
given drug (For reviews, see Robinson & Berridge, 1993, 2000, 2001, 2003; 
Steketee & Kalivas, 2011).  
Behavioral sensitization is a phenomenon in which prior exposure to a 
drug leads to an enhanced behavioral response to later administration of that 
drug (For reviews, see Robinson & Berridge, 1993, 2000, 2001, 2003; Steketee 
& Kalivas, 2011).  In animals, this occurs through the process of induction, or the 
pre-exposure phase, in which the animal is exposed to the drug either once or 
numerous times; and expression, or the test phase, when the animal is exposed 
to the drug after a period of abstinence (For reviews, see Robinson & Berridge, 
1993, 2000, 2001, 2003; Steketee & Kalivas, 2011).  Behavioral sensitization can 
be assessed by monitoring changes in stereotyped and non-stereotyped 
behaviors during both the induction and expression phases (For reviews, see 
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Robinson & Berridge, 1993, 2000, 2001, 2003; Pierce & Kalivas, 1997; Steketee 
& Kalivas, 2011).  Stereotyped behaviors include actions such as gnawing, 
licking, and undirected sniffing whereas non-stereotyped behaviors include 
exploratory sniffing, locomotor activity, and rearing (Rubino, Viganò, Massi & 
Parolaro, 2001).  Sensitization can be affected by associative processes such 
that the enhanced behavioral effect is stronger or exclusively observed when the 
animal is tested in the same environment in which the drug was initially given 
(For review, see Robinson, Browman, Crombag & Badiani, 1998).  This type of 
sensitization is referred to as context-dependent sensitization whereas 
sensitization that is apparent without a consistent context is known context-
independent sensitization (For review, see Robinson et al., 1998).  
Adult Sensitization 
Dose-dependence  
Sensitization can be dependent on the amount of drug that is given.  For 
example, psychostimulants cause a dose-dependent enhanced behavioral 
response such that low doses of psychostimulants produce sensitization but the 
intensity of the sensitized behavior becomes more robust with higher doses 
(Browman, Badiani, & Robinson, 1998a, 1998b; Davidson, Lazarus, Lee & 
Ellinwood, 2002; Frantz, O’Dell, & Parsons, 2007). 
Multi-trial vs. Single-trial Sensitization 
An enhanced behavioral response may occur after a number of pre-
exposures or only one pre-exposure to a drug.  Both psychostimulant induced 
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multi-trial and single-trial sensitization have been extensively examined.  During 
multi-trial sensitization, the animal is pretreated with the drug repeatedly over a 
period of time (typically at daily intervals) and then examined for changes in 
behavior after an abstinence period (for reviews, see Pierce & Kalivas, 1997; 
Steketee & Kalivas, 2011).  The sensitized response in single-trial sensitization 
tends to require a relatively high dose of the drug (Battisti, Chang, Uretsky & 
Wallace, 1999; Fontana, Post & Pert, 1993).  The expression of the sensitized 
response can persist long after the animal has been exposed to the drug (Leith & 
Kuczenski, 1982).  This enhanced behavioral responsiveness after one or many 
drug exposures may be relevant to drug relapse and the continuation of drug use 
(Robinson & Berridge, 1993). 
 Psychostimulant induced multi-trial sensitization can been seen after 
short and long periods of abstinence.  For example, adult rats given cocaine for 4 
consecutive days show a sensitized response 48 hr later (Laviola, Wood, Kuhn, 
Francis & Spear, 1995).  Sensitization to 5 days of repeated cocaine exposure is 
observed in adult rats after a 3 week abstinence period (Ujike, Tsuchida, 
Akiyama, Fujiwara, & Kuroda, 1995).  Furthermore, the persistence of multi-trial 
sensitization can also be seen after a 12 week abstinence period when 
pretreated for 6 days with amphetamine (Leith & Kuczenski, 1982). 
 Nonetheless, multiple days of pre-exposure are not necessary to cause 
an enhanced behavioral response because adult rats given a single pretreatment 
injection of cocaine show a sensitized response to the drug 24 hr later 
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(McDougall, Baella, Stuebner, Halladay & Crawford, 2007).  This can also be 
observed in adult mice when given single pretreatment injection of amphetamine 
and examined for sensitization 24 hr later (Battisti et al., 1999).  Although the 
persistence of single-trial psychostimulant sensitization is not as apparent as is it 
with multiple exposures, mice exposed to single injection of methamphetamine 
have shown a sensitized response up to 21 days after exposure (Jing et al., 
2014).  
Context-dependent vs. Context-independent Sensitization 
Differences in sensitization occur depending on the environment in which 
the drug was given (For review, Robinson et al., 1998).  Multi-trial behavioral 
sensitization is stronger when the induction and expression of psychostimulant 
sensitization are conducted in the same environment but is apparent if the 
environments are not the same (For review, Robinson et al., 1998).  Adult rats 
given psychostimulants show context-independent sensitization although it is not 
as robust as with context-dependent sensitization (Crombag, Badiani, Maren & 
Robinson, 2000; Badiani, Browman & Robinson, 1995; Browman et al., 1998a; 
1998b; Laviola et al., 1995).  This demonstrates that the enhanced behavioral 
response associated with multi-trial sensitization is sensitive to, but not 
dependent on, the context that the drug is given in (Crombag et al., 2000; 
Baldiani et al., 1995; Laviola et al., 1995).  One-trial sensitization, however, is 
completely context-dependent in adult rats (McDougall et al., 2007).  This means 
that a single pre-exposure to a psychostimulant, such as cocaine, will not cause 
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behavioral sensitization if the rat is challenged with cocaine in a different 
environment (Fontana, Post & Pert, 1993; McDougall et al., 2007; Weiss, Post, 
Pert, Woodward & Murman, 1989).  Therefore, the associative context of drug 
exposure modulates the intensity of the sensitized response in adult rats.  
Adolescent Sensitization 
Multi-trial vs. Single-trial Sensitization 
Multi-trial psychostimulant induced behavioral sensitization is also 
apparent early adolescent (PD 28) and late adolescent (PD 42) rats (Caster, 
Walker & Kuhn, 2005).  Specifically, when these male Sprague-Dawley rats are 
exposed to escalating doses of cocaine both age groups express sensitization 
after multiple drug exposures but early adolescent animals show a more robust 
sensitization compared late adolescent rats (Caster et al., 2005).  Adolescent 
animals also display gender differences after repeated treatment with the 
psychostimulant methylphenidate, as Sprague-Dawley female rats show 
enhanced locomotor activity compared to males (Chelaru, Yang & Dafny, 2012).  
Furthermore, repeated exposure to cocaine during adolescence causes a 
persistent sensitized response that can be observed after a short (PD 37) and/or 
long (PD 64) abstinence period (Marin, Cruz & Planeta, 2008). 
The effects of psychostimulants using one trial sensitization are similar to 
what has been observed with multiple trial sensitization during adolescent 
development.  Young rats (PD 19) given a single pretreatment injection of 
cocaine show a sensitized locomotor response for up to 5 days after initial drug 
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exposure (McDougall et al., 2009).  Both early adolescent (PD 28) and late 
adolescent (PD 42) rats show a sensitized behavioral response to a single high 
dose of cocaine, although this response is more robust in the younger animals 
(Caster, Walker & Kuhn, 2007).  Additionally, amphetamine sensitization is 
observed in early adolescent rats (PD 30) when tested 2 or 30 days later (PD 60; 
Mathews, Kelly & McCormick, 2011).  Overall, psychostimulant induced 
behavioral sensitization is observed in pre-adolescent and adolescent rats using 
both single-trial and multi-trial procedures.  
Associative vs Non-associative Sensitization 
Context is not as important for sensitization in young rats as it is in adult 
rats. Preweanling rats (PD 19) given a single pretreatment injection of cocaine 
show both context-dependent and context-independent sensitization for up to 5 
days with a 10 mg/kg challenge of cocaine (McDougall et al., 2007).  In fact, 
these young rats actually showed stronger sensitization in a context-independent 
environment relative to a context-dependent environment (McDougall et al., 
2007).  Stronger sensitization in a context-independent environment can be seen 
1 and 3 days after exposure (McDougall et al., 2009).  
Although young rats experience context-independent sensitization after a 
short abstinence period, environmental conditioning is important for sensitization 
in these pups after a longer drug-free period (Zavala, Nazarian, Crawford & 
McDougall, 2000).  Specifically, rat pups pretreated for 5 days with cocaine only 
show context-dependent sensitization after a 7-day drug free period; whereas, 
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after 1 day of abstinence, preweanling pups show both context-independent and 
context-dependent sensitization (Zavala et al., 2000).  
Behavioral Sensitization using Cannabinoids 
Although behavioral sensitization has become a common tool for studying 
abused drugs, relatively little sensitization research has been conducted with 
cannabinoids.  This is especially true when examining early and late adolescent 
rats.  Cannabinoids, like psychostimulants, can produce behavioral sensitization 
that persists after the discontinuation of drug use (Rubino et al., 2001).  In the 
first report of cannabinoid multi-trial sensitization, adult Sprague-Dawley male 
rats were pretreated with THC twice a day for 5 days (Rubino et al., 2001).  All 
animals received a dosage regimen in which the amount of THC administration 
increased over the 5-day period (5, 10, 20, 40 and 40 mg/kg) and sensitization 
was assessed after a long abstinence period of 20 days (Rubino et al., 2001).  
Pretreatment with THC sensitized behaviors associated with stereotyped activity 
including gnawing, licking, and undirected sniffing after a 5 mg/kg THC challenge 
injection.  Furthermore, a trend was noticed in non-stereotype activities, including 
a slight increase in forward locomotion, sniffing, and rearing (Rubino et al., 2001).  
Different patterns of sensitization occur depending on the length of 
exposure and the dose of THC administered.  After 3 days of an increasing THC 
regime (2, 4, and 8 mg/kg), adult male Sprague-Dawley rats exhibited enhanced 
non-stereotyped activity when challenged 14 days later with THC (150 μg/kg 
intravenous; Cadoni, Pisanu, Solinas, Acquas & Chiara, 2001; Cadoni, Valentini 
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& Di Chiara, 2008).  This enhancement may have occurred due to the short 
exposure period to THC and short abstinence period (Cadoni et al., 2001; 
Cadoni, Valentini & Di Chiara, 2008).  Overall, pretreatment with THC can cause 
changes to both non-stereotyped and stereotyped behaviors that are associated 
with an increased sensitized response to the drug.  
Like THC, the synthetic cannabinoid agonist WIN 55,212-2 can cause the 
induction of behavioral sensitization after a single exposure or multiple exposures 
(Enayatfard et al., 2013).  Specifically, an enhanced behavioral response to WIN 
55,212-2 was seen after a single pretreatment administration of a low dose (0.1 
kg/mg, IP) when compared to saline-pretreated rats.  After a 10-day regimen of 
WIN 55,212-2 pretreatment rats also showed a sensitized response that 
persisted 48 hr after the final pretreatment day (Enayatfard et al., 2013).  
Furthermore a single exposure to WIN at a low dose has been shown to increase 
locomotor responses whereas a single exposure to a high dose of WIN did not 
enhance motor activity in the open field test (Drews et al., 2005). 
Cross-sensitization with Other Drugs  
Interestingly, the ability of cannabinoids to cross-sensitize with other drugs 
has been examined more thoroughly than it has been for cannabinoid-induced 
sensitization.  For example, in adults, a single pre-exposure to either THC or WIN 
55,212-2 increases sensitization to amphetamine when given 30 min later 
(Gorriti, de Fonseca, Navarro & Polomo, 1999; Muschamp & Siviy, 2002).  Also, 
multiple exposures of THC or WIN 55,212-2 increases the sensitized response to 
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amphetamine (Gorriti et al., 1999; Muschamp & Siviy, 2002).  WIN 55,212-2, 
when acutely injected, affects both ambulatory and rearing activity of animals that 
are given amphetamine 30 min later (Muschamp & Siviy, 2002).  When these 
adult rats are exposed to WIN 55,212-2 for 10 days, an increase in ambulatory 
movement and rearing activity is observed after a challenge injection of 
amphetamine (Muschamp & Siviy, 2002).  Additionally, adult rats treated with 
morphine show an increased behavioral response when pretreated with a low or 
high dose of either THC or CP (Cardoni et al., 2001; Cardoni et al., 2008; 
Norwood, Cornish, Mallet & McGregor, 2003). 
Ontogeny of Cannabinoid Sensitization 
Unfortunately, very limited research has been conducted on the ontogeny 
of cannabinoid sensitization.  At present, it is unknown whether cannabinoid 
sensitization, like psychostimulant sensitization, would differ between adolescent 
and adult rats.  Interestingly, there has been one investigation that showed, that 
an 8-day THC pretreatment induced a sensitized response to a cocaine 
challenge in late adolescent rats but not in adult rats (Dow-Edwards & 
Izenwasser, 2012). 
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CHAPTER SIX 
SUMMARY THESIS STATEMENT 
Both the medical and recreational use of cannabis are now decriminalized 
in California and many other states.  Since the change in these state laws, there 
has been surges in the availability and use of cannabis (Cerdá, Wall, Keyes, 
Galea & Hasin, 2012; Hasin et al., 2015).  A major concern with the rise in 
societal acceptance of cannabis and the increased availability of this drug is 
higher use rates in adolescent populations (Kosterman, Hawkins, Guo, Catalano, 
& Abbott, 2000).  Escalation of cannabis use in adolescents is important because 
the risk of developing cannabis use disorder is stronger in people who start drug 
use early (Richter, Pugh & Ball, 2016).  The use of cannabis before the age of 15 
increases the likelihood of becoming a chronic user and enhances the probability 
of experimenting with other illicit drugs (Nelson, Van Ryzin, & Dishion, 2015; 
Prince van Leeuwen et al., 2014; Richter et al., 2016).  Moreover, adolescent use 
of cannabis can cause long-term consequences, including problems with 
executive functioning, that are not apparent in users that begin after the age of 
15 (Fontes et al., 2011).  
The cause for the inflation in problematic cannabis use with early onset is 
unknown but an increase in the addictive properties of cannabis during this 
developmental period may partially account for this.  To this end, the present 
thesis focused on the adolescent response to cannabis using the behavioral 
sensitization paradigm. Behavioral sensitization is an animal model used to study 
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craving, which is an important component of drug addiction (Berridge & 
Robinson, 1995; For reviews, see Robinson & Berridge, 1993, 2000, 2001, 
2003).  In this model, drugs with addictive properties induce an augmented 
behavioral response in animals after prior exposure to the drug (for reviews, see 
Robinson and Berridge, 1993, 2000, 2001, 2003; Steketee & Kalivas, 2011).  
Behavioral sensitization can be measured as changes in stereotypical and non-
stereotypical behaviors (For reviews, see Steketee & Kalivas, 2011; Pierce & 
Kalivas, 1997).  Behavioral sensitization is sensitive to changes in environmental 
contexts, number of drug pre-exposures, and developmental stage.  
Currently, no studies have examined developmental differences in 
behavioral sensitization to cannabinoids and very little data exists on the acute 
effects of cannabinoids adolescence (For reviews, see Jacobus & Tapert, 2014; 
Viveros, Llorent, Moreno, & Marco, 2005).  Thus, the purpose of this thesis was 
to examine the effects of the cannabinoid agonist CP in early adolescent 
Sprague-Dawley rats (PD 30-36) using the behavioral sensitization paradigm. CP 
was used because it mimics the effects of THC, the primary psychoactive 
ingredient in cannabis (Gurney, Scott, Kacinko, Presley & Logan, 2014).  
Specifically, this study assessed the ability of CP to induce behavioral 
sensitization in adolescent rats and determine if there are gender differences in 
the sensitization to CP.  In addition, we also examined the ability of CP to induce 
cross-sensitization to cocaine in adolescent rats.  
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Despite the limited data available on developmental sensitization to 
cannabinoids, the following four hypotheses were formulated: 
1. Repeated treatment with CP would induce a sensitized behavioral 
response in male and female adolescent rats. 
As mentioned above, there is limited data on the response of adolescent 
rats to cannabinoid agonists.  However, based on the adult literature assessing 
behavioral sensitization with cannabinoid agonists (Cadoni et al., 2001; Cadoni et 
al., 2008; Enayatfard et al., 2013; Rubino et al., 2001) and literature showing that 
adolescent rats are more often more sensitive to drug exposure than adults (For 
review, see Izenwasser, 2005), it was predicted that repeated treatment with the 
CP compound would result in a augmented behavioral response in adolescent 
rats. 
2. Female adolescent rats would show a greater behavioral response to CP 
than male adolescent rats.  
Gender differences are common in the behavioral response to drugs of 
abuse. Adult female rats are more sensitive to the behavioral effects of 
cannabinoids because female rats given either THC or CP have a greater 
antinociceptive response, show increased catalepsy, and display more 
spontaneous locomotor activity compared to male rats (Tseng & Craft, 2001).  
Additionally, female rats display greater sensitization to psychostimulants 
(Chelaru et al., 2012).  Based on the evidence that female rats display greater 
sensitivity to cannabinoids in other behavioral measures using cannabinoids and 
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show enhanced behavioral sensitization to psychostimulants, it was 
hypothesized that female rats would show stronger behavioral sensitization to the 
cannabinoid agonist CP than male rats. 
3. Cocaine would induce behavioral sensitization and conditioned activity in 
both male and female adolescent rats.  
Cocaine-induced sensitization and conditioned activity are both well 
documented phenomenon in rats.  Cocaine sensitization can be observed in rats 
as early as PD 19 and has been previously demonstrated in adolescent rats 
(Caster et al., 2005, 2007; McDougall et al., 2007, 2009).  In contrast, 
conditioned activity is not found in preweanling and preadolescent rats but is 
quite robust and persistent in adult rats (McDougall et al., 2014).  Based on this 
literature, it was expected that adolescent rats would show a cocaine sensitized 
response.  We also believed that both the male and female adolescent rats 
would respond in an adult like manner and show conditioned activity. 
4. Repeated treatment with CP would induce a sensitized response to 
cocaine. 
Early adolescent exposure to cannabis increases the likelihood of using other 
drugs of abuse in human adolescents (Haberstick et al., 2014; Peer et al., 2013; 
Farmer et al., 2015).  The reason for this increased vulnerability is unclear as it is 
not known whether environmental/social issue drive the increased drug use or 
changes in neuronal functioning after cannabis exposure.  In adult and later 
adolescent rats there is data showing that exposure to THC or WIN can cause a 
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sensitized response amphetamine, cocaine and morphine (Dow-Edwards & 
Izenwasser, 2012; Cardoni et al., 2001; Cardoni et al., 2008; Gorriti et al., 1999; 
Muschamp & Siviy, 2002).  We predicted that early adolescent rats given 
repeated injections of CP would also show a sensitized response to cocaine. 
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CHAPTER SEVEN 
MATERIALS AND METHODS 
Subjects 
Male and female rats (N = 283) of Sprague-Dawley descent (Charles 
River; Hollister, CA) were used. Rats were in early adolescence at the time of 
pretreatment (PD 30- PD 34) and testing (PD 36).  All rats were bred and raised 
in the vivarium of the Psychology Department of California State University, San 
Bernardino.  Dams and pups were housed in maternity cages that were large 
polycarbonate clear boxes (56 × 34 × 22 cm) with a wire lid.  Litters were culled 
on PD 3 to 10 pups per dam and pups were group housed (3-4 per cage) away 
from dams on PD 23.  All cages had Tek-Fresh® bedding (Harlan, Indianapolis, 
IN).  All animals received food and water ad libitum and kept on a12 hour light 
and 12 hour dark cycle.  Behavioral testing took place during the light cycle with 
subjects returned to their home cage after testing.  All subjects were handled 
according to the “Guide for the Care and Use of Laboratory Animals” (National 
Research Council, 2010) under a research protocol approved by the Institutional 
Animal Care and Use Committee of California State University, San Bernardino.  
Apparatus 
All behavioral testing was performed in commercially available activity 
monitoring chambers (41 × 41 × 41 cm) from Coulbourn Instruments (Allentown, 
PA, USA).  These chambers were kept in a separate testing room away from the 
animal colony.  The activity chambers consist of four acrylic walls, a gray plastic 
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floor, and an open top.  To measure horizontal locomotor activity or distance 
traveled, each chamber included an X-Y photobeam array with 16 photocells and 
detectors with a photobeam resolution of 0.76 cm.  The position of each rat was 
determined every 100 ms (i.e., the sampling interval).  Each chamber was 
equipped with a video camera centered above the chamber. 
Drugs 
CP and cocaine were purchased from Sigma Aldrich (St. Louis, MO).  The 
CP drug was mixed in a 50% dimethyl sulfoxide (DMSO)/ water solution and 
cocaine was mixed in saline.  All injections were given intraperitoneally (IP) at a 
volume of 1.0 ml/kg.  
Procedure and Statistical Analysis 
Experiment 1.  Effect of Dose on CP-induced Multi-trial Sensitization in 
Early Adolescent Male and Female Rats.  Adolescent rats (N= 137) were given 
five pretreatment days (PD 30-PD 34), a 48 hr abstinence period, and one test 
day (PD 36; see Table 1).  During pretreatment, rats were given CP (4, 13.2, or 
40 µg/kg, IP) or vehicle in the testing room and then placed immediately into the 
activity chambers.  Following a 10 min habituation period, distance traveled and 
stereotyped movements were measured for 60 min.  After the 48 hr abstinence 
period, half of the rats in each drug group received 4 µg/kg CP and the other half 
received 13.2 µg/kg CP.  Test day injections of CP were given in the testing room 
and rats were placed in activity chambers for 120 min.  Similar to the conditioning 
days, behavioral monitoring began after a 10 min habituation period. 
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Table 1.     
Experiment 1 Design and Timeline 
 Pretreatment 
age 
Pretreatment doses 
CP 55,940 
Test age Test dose of 
CP 55,940 
Male or 
Female 
PD 30-PD 34 
0, 4, 13.2 or 40 
µg/kg 
PD 36 4 or 13.2 µg/kg 
 
 
Experiment 1 Analyses. Distance traveled and repetitive movement data 
for the pretreatment sessions were analyzed by separate three-way (sex × 
pretreatment drug × day) mixed factorial ANOVAs.  Test day data was analyzed 
by separate four-way (sex × pretreatment drug × test day drug × time block) 
mixed factorial ANOVAs.  Significant higher-order interactions were further 
analyzed using two- or one-way ANOVAs.  Post hoc analysis were made using 
Tukey tests (p < 0.05).  Litter effects were controlled through experimental 
design, with no more than one subject per litter being assigned to a particular 
group.  
Experiment 2.  Cross-sensitization between CP 55,940 and Cocaine in 
Early Adolescent Male and Female Rats.  Adolescent rats (N= 146) were given 
five pretreatment days (PD 30- PD 34), a 48 h abstinence period, and one test 
day (PD 36), (see Table 2).  The CP pretreatment doses (13.2 or 40 µg/kg) were 
determined from Experiment 1, cocaine (20 mg/kg) and vehicle (DMSO or 
Saline).  All rats were given one daily IP injection in the experimental chamber.  
After rats received their injection in the experimental room they were placed in 
activity chambers.  After a 10 min habituation period distance traveled and 
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stereotyped movements were measured for 60 min.  On the test day (PD 36), all 
animals received an IP injection of cocaine (10 mg/kg) or saline and after 10 min 
distance traveled and stereotyped movement were measured for 120 min.  
 
 
Table 2.     
Experiment 2 Design and Timeline 
 Pretreatment 
age 
Pretreatment dose Test 
age 
Test dose 
 
Male or 
Female 
PD 30- PD 34 
13.2 µg/kg CP 55,940 
40 µg/kg CP 55,940 
20 mg/kg Cocaine 
Vehicle 
PD 36 
10 mg/kg 
Cocaine 
Saline 
 
 
 
Experiment 2 Analyses.  Distance traveled and stereotyped movement 
data for the pretreatment sessions were analyzed by separate three-way (sex × 
pretreatment drug × day) mixed factorial ANOVAs.  Test day data was analyzed 
by separate four-way (sex x pretreatment drug× test drug × time block) mixed 
factorial ANOVAs.  Significant higher-order interactions were further analyzed 
using two- or one-way ANOVAs.  Post hoc analysis of data was made using 
Tukey tests (p < 0.05).  Litter effects were controlled through experimental 
design, with no more than one subject per litter being assigned to a particular 
group. 
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CHAPTER EIGHT 
RESULTS 
Experiment 1 examined the dose-response relationship of cannabinoid-
induced sensitization.  It was predicted that female rats would display an overall 
greater sensitivity to the cannabinoid doses and that both males and females 
would show cannabinoid induced sensitization through increased distance 
traveled and stereotyped movement.  
During the pretreatment period a significant main effect of sex was 
observed in distance traveled scores, F(1,127) = 5.478, p = .02.  Specifically, 
females had greater distance traveled scores compared to their male 
counterparts.  However, there was no significant main effect of sex in 
stereotyped movement, F(1,127) = 3.128, p = .11 (Fig. 1).  There was also a 
trend for a main effect of conditioning drug for distance traveled, F(3,127) = 
2.485, p = .06.  This trend was primarily between the vehicle and 40 μg/kg CP 
group, as animals treated with the high cannabinoid dose showed less activity 
than rats given vehicle.  There was no main effect of the conditioning drug 
observed in stereotyped movement, F(3,127) = 2.076, p = .11.  Lastly, no 
interaction occurred between sex and conditioning drug for distance traveled, 
F(3,127) = 1.400, p = .25 or stereotyped movement, F(3,127) = 0.934, p = .43.  In 
summary, there was no difference in the behavioral response of rats given 
cannabinoids or vehicle during the conditioning phase (Fig. 2). 
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Figure 1.  Experiment 1 Conditioning Days by Gender 
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of 
male and female adolescent rats injected with CP 55,940 (4, 13.5, 40 μg/kg, IP) 
or vehicle and placed in photobeam activity chambers for five conditioning days 
(PD 30-34). Data on this graph were collapsed across conditioning drug group.  A 
Indicated a significant difference from male rats over the 5 day conditioning 
phase. 
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Figure 2.  Experiment 1 Conditioning Days by Conditioning Drug 
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of 
male and female adolescent rats injected with CP 55,940 (4, 13.2, 40 μg/kg, IP) 
or vehicle and placed in photobeam activity chambers for 5 conditioning days 
(PD 30-34).  
 
 
On the test day, treatment with CP differentially altered stereotyped 
movements, F(1,121) = 7.58, p < 0.001, as rats treated with the low dose of CP 
(4 μg/kg) had more stereotyped movements (M = 683.81, SEM = 29.14) than rats 
given the higher dose of CP (13.2 μg/kg)  (M = 570.73, SEM = 26.42).  Distance 
traveled scores did differ for the two CP drug doses, F(1,121) = 2.755, p = 0.10 
(figure not shown).  Pretreatment with CP at all doses failed to significantly 
enhance distance traveled scores, F(3,121) = 1.099, p = 0.35, or stereotyped 
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movements, F(3,121) = .753, p = 0.52 on the test day.  Lastly, there was no 
interaction between sex, condition drug and test day drug for distance traveled, 
F(3,121) = .878, p = 0.45; (Fig. 3) or stereotyped behaviors, F(3,121) = .581, p = 
0.63 (Fig. 4).  These results indicate that cannabinoid pre-exposure did not 
increase the behavioral response to a cannabinoid agonist in either female or 
male adolescent rats. 
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Figure 3.  Experiment 1Test Day Distance Traveled 
Mean distance traveled scores (± SEM) of male and female adolescent rats 
injected with CP 55,940 (4, 13.2, 40 μg/kg, IP) or vehicle and placed in 
photobeam activity chambers on the five conditioning days (PD 30-34) and then 
challenged with CP 55,940 (4 or 13.2 μg/kg, IP) on test day (PD 36). 
47 
 
0
5 0
1 0 0
1 5 0
2 0 0
4  g /k g  C P  5 5 ,9 4 0  M a le s
S
te
r
e
o
ty
p
e
d
 M
o
v
e
m
e
n
t
4  g /k g  C P  5 5 ,9 4 0  F e m a le s
V e h ic le
C P  4 0  µ g /k g
C P  1 3 .2  µ g /k g
C P  4  µ g /k g
2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4
0
5 0
1 0 0
1 5 0
1 3 .2  g /k g  C P  5 5 ,9 4 0  M a le s
S
te
r
e
o
ty
p
e
d
 M
o
v
e
m
e
n
t
2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4
1 3 .2  g /k g  C P  5 5 ,9 4 0  F e m a le s
T im e b lo c k
  
Figure 4.  Experiment 1 Test Day by Stereotyped Movement 
Mean stereotyped movements (± SEM) of male and female adolescent rats 
injected with CP 55,940 (4, 13.2, 40 μg/kg, IP) or vehicle and placed in 
photobeam activity chambers on the five conditioning days (PD 30-34).  On PD 
36, rats were injected with (4 or 13.2 μg/kg, IP) and placed in photobeam activity 
chambers for 2 h. 
 
 
Experiment 2 examined conditioned activity and behavioral sensitization in 
adolescent rats after pretreatment with either cocaine or CP and then a challenge 
injection of cocaine or vehicle.  During the pretreatment phase, the conditioning 
drug  significantly altered distance traveled scores, F(3,131) = 561.359, p< .001 
and stereotyped movement, F(3,131) = 160.957, p < .001.  That is, male and 
female rats given cocaine had greater activity levels than rats treated with CP (40 
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or 13.2 ug/kg) or vehicle (Tukey test, p < .01).  The increase in stereotyped 
movement occurred across all 5 days of conditioning (conditioning drug × day 
interaction), F(9,413) = 8.021, p < .001.  In contrast, conditioning drug effects 
were not altered by day for distance traveled, F(8,364) = 1.760, p = .08 (Fig. 5).  
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Figure 5.  Experiment 2 Conditioning Days by Conditioning Drug 
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of 
adolescent rats injected with CP 55,940 (13.2 or 40 μg/kg), cocaine (20 mg/kg) or 
vehicle and placed in photobeam activity chambers on the five conditioning days 
(PD 30-34).  A Indicates a significant difference in activity for cocaine-pretreated 
animals compared to CP 55,940 and vehicle-treated animals. 
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On the test day, treatment with the test drug differentially altered distance 
traveled scores, F(3,129) = 91.575, p < .001 and stereotyped movements 
F(3,129) = 110.520, p < .001.  Specifically, rats challenged with cocaine 
displayed significantly more locomotor activity compared to rats challenged with 
vehicle.  This enhancement in activity remained significant across all 24 time 
blocks for both distance traveled, F(3, 366) = 30.132, p < .001, and stereotyped 
movement, F(6,775) = 7.652, p <.001 (Fig. 6).  
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Figure 6.  Experiment 2 Test Day by Test Drug 
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of 
male and female adolescent rats injected with CP 55,940 (13.2 or 40 μg/kg, IP), 
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cocaine (20 mg/kg, IP) or vehicle and placed in photobeam activity chambers on 
five conditioning days (PD 30-34).  On PD 36, rats were injected with cocaine (10 
mg/kg, IP) or vehicle and placed in photobeam activity chambers for 2 h.  Data in 
this graph were collapsed across conditioning drug group. A Indicated a 
significant difference between cocaine- and saline- challenged animals on the 
test day.  
 
 
Rats given saline on the test day were analyzed separately to assess 
conditioned activity.  Both distance traveled scores, F(3,57) = 10.49, p <.001 and 
stereotyped movement, F(3,57) = .59, p < .001 were altered depending on the 
conditioning drug given.  Specifically, rats pretreated with cocaine had 
significantly greater locomotor activity than vehicle-pretreated rats (Tukey test, p 
< .01).  Pretreatment with the CP drug did not alter saline-induced activity (Fig. 
7).  Sex did not alter the behavior of rats given saline on the test day for distance 
traveled, F(3,57) = 1.31, p = .25 or stereotyped movements, F(3,57) = 1.87, p = 
.17. 
Rats given cocaine on the test day showed significant differences in 
distance traveled, F(3,72) = 3.16, p = .03 and stereotyped behaviors, F(3,72) = 
3.05, p =. 03 depending on the conditioning drug given because, rats pretreated 
with cocaine had significantly greater distance traveled scores and stereotyped 
movements compared saline-pretreated rats (Tukey test, p < .01; Fig. 8).  Sex 
did not significantly alter either distance traveled F(3,72) = 1.80, p = .18 or 
stereotyped movements, F(3,72) = .02, p = .88 of rats given cocaine on the test 
day.  In contrast to cocaine-pretreated animals, rats pretreated with CP (13.2 or 
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40 μg/kg) did not have significantly enhanced distance traveled scores (Tukey 
test, p > 0.05) and stereotyped movement (Tukey test, p > 0.05) compared to 
vehicle-pretreated animals on the test day (Fig. 7 and 8).   
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Figure 7.  Experiment 2 Test Day Saline by Conditioning Drug. 
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of 
adolescent rats injected with CP 55,940 (13.2 or 40 μg/kg, IP), cocaine (20 
mg/kg, IP) or vehicle and placed in photobeam activity chambers on five 
conditioning days (PD 30-34).  On PD 36, rats were injected with saline and 
placed in photobeam activity chambers for 2 h.  *Indicates significant difference 
between cocaine-treated rats and rats treated with either saline or CP 55,940.  
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Figure 8.  Experiment 2 Test Day Cocaine by Conditioning Drug 
Mean distance traveled scores (± SEM) and stereotyped movements (± SEM) of 
adolescent rats injected with CP 55,940 (13.2 or 40 μg/kg, IP) cocaine (20 mg/kg, 
IP), or vehicle and placed in photobeam activity chambers on five conditioning 
days (PD 30-34) On PD 36, rats were injected with cocaine (10 mg/kg, IP) and 
placed in photobeam activity chambers for 2 h.  *Indicates significant difference 
between cocaine-treated rats and rats treated with either saline or CP 55,940.  
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CHAPTER NINE 
DISCUSSION 
In two experiments, the present thesis examined the effects of repeated 
exposure to CP in early adolescent SD male and female rats using the 
behavioral sensitization paradigm.  In this paradigm, the behavioral response to a 
drug is assessed after prior exposure to that drug.  If the behavioral response is 
augmented when re-exposed to the drug, then sensitization has occurred.  
Behavioral sensitization has become an important tool in preclinical 
investigations, as a sensitized response to a drug is indicative of its abuse 
potential and is believed to be particularly associated with drug seeking behavior 
(Robinson & Berridge, 2003).  The first experiment examined whether repeated 
CP exposure, over a range of doses, would differentially affect behavior after a 
later challenge dose of CP.  The second experiment assesed effects of repeated 
CP exposure on later cocaine-induced behavioral sensitization and conditioned 
activity.  It was hypothesized that repeated CP would induce an augmented (i.e., 
sensitized) response to both CP (Experiment 1) and cocaine (Experiment 2) in 
male and female rats.  It was also predicted that female rats would have a 
greater sensitized response, when compared to males, and that both CP and 
cocaine would induce conditioned activity (Experiment 2). 
In contrast to the predictions, repeated exposure to CP in Experiment 1 
did not induce sensitization in adolescent rats at any dose or in either sex.  
Female rats were, however, more active than male rats during the pretreatment 
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phase.  Similar to Experiment 1, pretreatment with CP did not enhance cocaine-
induced activity or produce conditioned activity in adolescent rats.  In 
comparison, repeated exposure to cocaine did induce an augmented response to 
both cocaine (behavioral sensitization) and saline (conditioned activity) challenge 
in male and female adolescent rats.  
The failure to find CP-induced behavioral sensitization was somewhat 
surprising as a sensitized response to both synthetic cannabinoids and THC has 
been observed in adult rats (Cadoni et al., 2001, 2008; Rubino et al., 2001; 
Varvel, Martin & Lichtman, 2007).  For example, 10 days of treatment with the 
synthetic cannabinoid WIN (0.1 mg/kg) produced an augmented locomotor 
response after a 48 hr abstinence period (Enayatfard et al., 2013).  Adult rats 
also show behavioral sensitization after treatment with THC; however, a 
sensitized response is only observed when the dose of THC is increased each 
day during the pretreatment phase (Cadoni et al., 2001, 2008; Rubino et al., 
2001).  The use of an increasing dose regimen is believed to mimic recreational 
cannabis users who are likely to increase their dose over time (Ellickson, 
Martino, & Collins, 2004).  Adolescent rats are often more sensitive to 
psychoactive drugs than adult rats (For review, see Izenwasser, 2005), so it was 
expected that they too would show a sensitized response.  A possible 
explanation is that cannabinoids may be different from other psychoactive 
compounds, with adolescents showing less behavioral activation after exposure 
(McKinney et al., 2008). 
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Alternately, the inability to observe sensitization to CP may be a 
consequence of our procedures.  In behavioral sensitization studies the drug is 
typically given once a day for a 1 to 10 day period (Caster et al., 2005; 
Enayatfard et al., 2013; Kozanian, Gutierrez, Mohd-Yusof & Mc Dougall, 2012; 
McDougall, Duke, Bolanos & Crawford, 1994; McDougall et al., 2007; Robinson 
& Berridge, 1993; Vezina, 1996).  In many of the investigations showing 
cannabinoid sensitization, the drug was either given in an escalating dose or 
multiple doses were given each day (Cadoni et al., 2001, 2008; Enayatfard et al., 
2013; Rubino et al., 2001).  This pattern suggests that the neuronal modifications 
necessary to induce sensitization after cannabis exposure requires a more 
intense treatment  than drugs such as cocaine and amphetamine, which produce 
sensitization after a single exposure (Caster et al., 2007; McDougall et al., 2009).  
Therefore, it is likely that cannabis sensitization in adolescents may be possible 
with a more intense dosing paradigm (Cadoni et al., 2001, 2008; Enayatfard et 
al., 2013; Mathews et al., 2011; Rubino et al., 2001).  Importantly, these data 
may suggest that enhanced drug sensitivity can only be seen in populations that 
escalate their dose; whereas, consistent dose regimens used for medicinal 
reasons (Häuser et al., 2018; Sulak, Saneto & Goldstein, 2017) may not have the 
same detrimental impact (Kononoff et al., 2018; Melas et al., 2018). 
It is also possible that the inability to find sensitization in adolescent rats is 
specific to the cannabinoid chosen for this investigation and is not indicative of 
other cannabinoids.  CP is a potent agonist of the CB1 receptor system 
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(Pertwee, 1997) and may not produce effects that are similar to other 
cannabinoids which cause sensitization (Cadoni et al., 2001, 2008; Enayatfard et 
al., 2013; Rubino et al., 2001).  The cannabis plant contains a number of 
cannabinoids that are not well understood and may contribute to the addictive 
properties of cannabis use (Andre, Hausman & Guerriero, 2016).  The synergistic 
relationship that of cannabinoids may contribute to the rewarding effects 
experienced by a user, and are not observed when a synthetic full CB1 agonist is 
examined (McLaughlin, 2018; Russo & Guy, 2006).   Thus, research focused on 
THC alone or synthetic cannabinoids may not be sufficient to understand the full 
behavioral response to cannabis.  It may be necessary to compare how animals 
respond to the effects of vaporizing the cannabis plant to gain a better 
understanding of cannabinoid sensitivity (Baxter-Potter, Lugo, Fuchs, & 
McLaughlin 2017; McLaughlin, 2018).  
This study also examined cocaine-induced sensitization and found that 
cocaine pre-exposure led to behavioral sensitization in adolescent rats.  Cocaine-
induced behavioral sensitization develops early in rats and can be observed in 
rats at PD 19 (McDougall et al., 2007), and thus, sensitization was not 
unexpected.  However, previous research has demonstrated a number of age-
dependent effects in the sensitization to cocaine (McDougall et al., 1994, 1999, 
2007; Zavala et al., 2000).  For instance, preweanling rats show cocaine 
sensitization at doses similar to adults; however, the sensitized response in 
preweanling rats does not show persistence and is not apparent after 7 days 
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(Zavala et al., 2000).  While sensitization in adult rats can be observed for 
months after the last drug exposure (Leith & Kuczenski, 1982).  Previous 
research also indicates that the adolescent sensitized response is not the same 
as an adult or preweanling rats (McDougall et al. 1994, 1999, 2007; Zavala et al., 
2000), as preweanling and adult rats show cocaine-induced sensitization after 
only one drug exposure while adolescent rats do not.  As predicted, this study 
also found conditioned activity in rats that were pretreated with cocaine and 
challenged with saline on the test day.  This finding showed that early adolescent 
rats respond in an adult-like fashion to the conditioning effects of cocaine.  
Although this thesis found that pre-exposure to cocaine led to sensitization 
after a cocaine challenge, there was no evidence that adolescent rats showed 
cannabinoid-induced cross-sensitization to cocaine.  Unlike CP, THC does 
induce cross-sensitization to cocaine in older adolescent rats, but only after 
increasing doses of cocaine (Dow-Edwards & Izenwasser, 2012).  Similarly, an 
escalating dose of WIN given to adolescent rats (PD 42) over an 11-day period 
causes cross-sensitization to cocaine (10 mg/kg) 24 h later (Melas et al., 2018).  
The present investigation showed that cross-sensitization to cocaine does not 
occur after a five-day consistent-dose regimen of CP, suggesting that a more 
intense drug exposure is necessary for cannabinoid sensitization to occur.  Thus, 
these data propose that changes in drug sensitivity may not occur in cannabis 
users that do not increase their doses.  For example, early high users that use a 
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consistent high dose of cannabis and stable light users that use a consistent low 
dose of cannabis (Ellickson et al., 2004). 
The failure to find sensitization or cocaine cross-sensitization after 
exposure to CP is inconsistent with the cannabis gateway theory of drug use.  
The gateway theory postulates that cannabis use increases the likelihood of later 
experimentation with illicit substances (Fergusson, Boden & Horwood, 2005; 
Secades-Villa, Garcia-Rodiguez, Jin, Wang, & Blanco, 2015).  A sensitized 
response to CP or cocaine would support the hypothesis that adolescent 
exposure to a cannabinoid causes an enhanced response when the individual is 
later exposed to these drugs.  Instead, we found that CP exposure did not lead to 
an enhanced behavioral response to CP or cocaine suggesting that the gateway 
theory does not apply with this combination or compounds.  In addition the lack 
of behavioral sensitization to CP suggests that moderate consistent treatment 
with a cannabinoids does not activate in physiological processes that drive drug 
seeking behavior.  This finding suggests that other factors, such as environment, 
mental health and economic status, may play a more vital role in an adolescent’s 
motivation to continue to use cannabis or experiment with other illicit substances 
(Fergusson et al., 2005; Secades-Villa et al., 2015).  
In conclusion, little is known about the adolescent response to cannabis 
exposure.  Acquiring this information is important to fully understand the abuse 
potential, addictive properties, and long term consequences of cannabinoid-
based therapies.  The present study examined the repeated exposure to the 
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synthetic cannabinoid agonist CP in adolescent male and female rats to assess if 
it would alter drug responsivity.  Our data indicated that repeated treatment with 
CP in adolescent rats does not alter drug responsivity to a later drug challenge of 
CP or cocaine.  These data suggest that the use of a consistent dose CP by 
adolescents does not alter drug sensitivity and is supportive of the medicinal use 
of cannabinoids; however, additional research, testing other cannabinoids, is 
wanted. 
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anandamide effects on food intake and sexual behavior of rats. Neuroscience 
Letters, 364(1), 1-6. 
Mathews, I. Z., Kelly, H., & McCormick, C. M. (2011). Low doses of amphetamine lead 
to immediate and lasting locomotor sensitization in adolescent, not adult, male 
rats. Pharmacology Biochemistry and Behavior, 97(4), 640-646. 
Matsuda, L. A., Bonner, T. I., & Lolait, S. J. (1993). Localization of cannabinoid receptor 
mRNA in rat brain. Journal of Comparative Neurology, 327(4), 535-550. 
McDougall, S. A., Baella, S. A., Stuebner, N. M., Halladay, L. R., & Crawford, C. A. 
(2007). Cocaine-induced behavioral sensitization in preweanling and adult rats: 
75 
 
Effects of a single drug–environment pairing. Psychopharmacology, 193(3), 323-
332. 
McDougall, S. A., Charntikov, S., Cortez, A. M., Amodeo, D. A., Martinez, C. E., & 
Crawford, C. A. (2009). Persistence of one-trial cocaine-induced behavioral 
sensitization in young rats: Regional differences in Fos immunoreactivity. 
Psychopharmacology, 203(3), 617-628. 
McDougall, S. A., Duke, M. A., Bolanos, C. A., & Crawford, C. A. (1994). Ontogeny of 
behavioral sensitization in the rat: effects of direct and indirect dopamine 
agonists. Psychopharmacology, 116(4), 483-490. 
McDougall, S. A., Pipkin, J. A., Der-Ghazarian, T., Cortez, A. M., Gutierrez, A., Lee, R. 
J., ... & Mohd-Yusof, A. (2014). Age-dependent differences in the strength and 
persistence of psychostimulant-induced conditioned activity in rats: effects of a 
single environment-cocaine pairing. Behavioural Pharmacology, 25(7), 695-704. 
McKenna, G. J. (2014). The current status of medical marijuana in the United States. 
Hawai’i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine 
and Public Health, 73(4), 105-108. 
McKinney, D. L., Cassidy, M. P., Collier, L. M., Martin, B. R., Wiley, J. L., Selley, D. E., 
& Sim-Selley, L. J. (2008). Dose-related differences in the regional pattern of 
cannabinoid receptor adaptation and in vivo tolerance development to Δ9-
tetrahydrocannabinol. Journal of Pharmacology and Experimental 
Therapeutics, 324(2), 664-673. 
76 
 
McLaughlin, R. J. (2018). Toward a translationally relevant preclinical model of cannabis 
use. Neuropsychopharmacology, 43(1), 213-214. 
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007). Cannabidiol–
recent advances. Chemistry and Biodiversity, 4(8), 1678-1692. 
Melas P. A., Qvist J. S., Deidda M., Upreti C., Wei Y. B., Sanna F., . . . & Kandel E. R. 
(2018). Cannabinoid modulation of eukaryotic initiation factors (eIF2α and 
eIF2B1) and behavioral cross-sensitization to cocaine in adolescent rats. Cell 
Reports, 22(11), 2909-2923. 
Murillo-Rodrıguez, E., Sanchez-Alavez, M., Navarro, L., Martınez-Gonzalez, D., 
Drucker-Colın, R., & Prospero-Garcıa, O. (1998). Anandamide modulates sleep 
and memory in rats. Brain Research, 812(1), 270-274. 
Muschamp, J. W., & Siviy, S. M. (2002). Behavioral sensitization to amphetamine 
follows chronic administration of the CB 1 agonist WIN 55,212-2 in Lewis rats. 
Pharmacology Biochemistry and Behavior, 73(4), 835-842. 
Musto, D. F. (1972). The marihuana tax act of 1937. Archives of General Psychiatry, 
26(2), 101-108. 
Nelson, S. E., Van Ryzin, M. J., & Dishion, T. J. (2015). Alcohol, marijuana, and tobacco 
use trajectories from age 12 to 24 years: Demographic correlates and young 
adult substance use problems. Development and Psychopathology, 27(01), 253-
277. 
Newton, D. E. (2014). Science and Political Controversy: A Reference Handbook: ABC-
CLIO. 
77 
 
Nithipatikom, K., Endsley, M. P., Isbell, M. A., Falck, J. R., Iwamoto, Y., Hillard, C. J., & 
Campbell, W. B. (2004). 2-Arachidonoylglycerol a novel inhibitor of androgen-
independent prostate cancer cell invasion. Cancer Research, 64(24), 8826-8830. 
Norwood, C. S., Cornish, J. L., Mallet, P. E., & McGregor, I. S. (2003). Pre-exposure to 
the cannabinoid receptor agonist CP 55,940 enhances morphine behavioral 
sensitization and alters morphine self-administration in Lewis rats. European 
Journal of Pharmacology, 465(1), 105-114. 
Oleson E.B., & Cheer J.F. (2012) A Brain on Cannabinoids: The role of dopamine 
release in reward seeking. Cold Spring Harbor Perspectives in Medicine, 
2(8):a012229. 
Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., & Hollister, L. E. 
(1986). Single‐dose kinetics of deuterium‐labelled cannabidiol in man after 
smoking and intravenous administration. Biological Mass Spectrometry, 13(2), 
77-83. 
Ohlsson, A., Lindgren, J. E., Wahlén, A., Agurell, S., Hollister, L. E., & Gillespie, H. K. 
(1982). Single dose kinetics of deuterium-labelled Δ1‐tetrahydrocannabinol in 
heavy and light cannabis users. Biological Mass Spectrometry, 9(1), 6-10. 
Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, 
R., & Shohami, E. (2001). An endogenous cannabinoid (2-AG) is neuroprotective 
after brain injury. Nature, 413(6855), 527-531. 
78 
 
Pearce, D. D., Mitsouras, K., & Irizarry, K. J. (2014). Discriminating the effects of 
cannabis sativa and cannabis indica: A web survey of medical cannabis users. 
Journal of Alternative and Complementary Medicine, 20(10), 787-791.  
Peer, K., Rennert, L., Lynch, K. G., Farrer, L., Gelernter, J., & Kranzler, H. R. (2013). 
Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use 
disorders in a largely substance dependent sample. Drug and Alcohol 
Dependence, 127(1), 215-219. 
Perez-Reyes, M. (1999). The psychologic and physiologic effects of active 
cannabinoids. In Marihuana and medicine (pp. 245-252). Humana Press, 
Totowa, NJ. 
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant 
cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9- 
tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215. 
Pertwee, R. G. (1997). Pharmacology of cannabinoid CB 1 and CB 2 receptors. 
Pharmacology & Therapeutics, 74(2), 129-180. 
Pertwee, R. G. (2005). Inverse agonism and neutral antagonism at cannabinoid CB 1 
receptors. Life Sciences, 76(12), 1307-1324. 
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, 
M. R., ... & Mechoulam, R. (2010). International Union of Basic and Clinical 
Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 
and CB2. Pharmacological Reviews, 62(4), 588-631 
79 
 
Pertwee, R. G., & Ross, R. A. (2002). Cannabinoid receptors and their ligands. 
Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 66(2), 101-121. 
Pierce, R. C., & Kalivas, P. W. (1997). A circuitry model of the expression of behavioral 
sensitization to amphetamine-like psychostimulants. Brain Research Reviews, 
25(2), 192-216. 
Prince van Leeuwen, A., Creemers, H. E., Verhulst, F. C., Vollebergh, W. A., Ormel, J., 
Oort, F., & Huizink, A. C. (2014). Legal substance use and the development of a 
DSM‐IV cannabis use disorder during adolescence: The TRAILS study. 
Addiction, 109(2), 303-311. 
Rajmohan, V., & Mohandas, E. (2007). The limbic system. Indian Journal of Psychiatry, 
49(2), 132–139. 
Richter, L., Pugh, B. S., & Ball, S. A. (2017). Assessing the risk of marijuana use 
disorder among adolescents and adults who use marijuana. American Journal of 
Drug and Alcohol Abuse, 43(3), 247-260. 
Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: an 
incentive-sensitization theory of addiction. Brain Research Reviews, 18(3), 247-
291. 
Robinson, T. E., & Berridge, K. C. (2000). The psychology and neurobiology of 
addiction: an incentive–sensitization view. Addiction, 95(8s2), 91-117. 
Robinson, T. E., & Berridge, K. C. (2001). Incentive‐sensitization and addiction. 
Addiction, 96(1), 103-114. 
80 
 
Robinson, T. E., & Berridge, K. C. (2003). Addiction. Annual Review of Psychology, 
54(1), 25-53. 
Robinson, T. E., Browman, K. E., Crombag, H. S., & Badiani, A. (1998). Modulation of 
the induction or expression of psychostimulant sensitization by the circumstances 
surrounding drug administration. Neuroscience & Biobehavioral Reviews, 22(2), 
347-354. 
Romero, J., De Miguel, R., Ramos, J. A., & Fernández-Ruiz, J. J. (1997). The activation 
of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA 
uptake. Life Sciences, 62(4), 351-363. 
Romero, J., Garcia-Palomero, E., Berrendero, F., Garcia-Gil, L., Hernandez, M. L., 
Ramos, J. A., & Fernandez-Ruiz, J. J. (1997). Atypical location of cannabinoid 
receptors in white matter areas during rat brain development. Synapse, 26(3), 
317-323. 
Romero, J., Garcia, L., Cebeira, M., Zadrozny, D., Fernandez-Ruiz, J. J., & Ramos, J. 
A. (1995). The endogenous cannabinoid receptor ligand, anandamide, inhibits 
the motor behavior: Role of nigrostriatal dopaminergic neurons. Life Sciences, 
56(23), 2033-2040. 
Rubino, T., Viganò, D., Massi, P., & Parolaro, D. (2001). The psychoactive ingredient of 
marijuana induces behavioural sensitization. European Journal of Neuroscience, 
14(5), 884-886. 
Russo, E. B. (2007). History of cannabis and its preparations in saga, science, and 
sobriquet. Chemistry & Biodiversity, 4(8), 1614-1648. 
81 
 
Russo, E., & Guy, G. W. (2006). A tale of two cannabinoids: the therapeutic rationale for 
combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses, 66(2), 
234-246. 
Sanchis‐Segura, C., & Spanagel, R. (2006). Review: behavioural assessment of drug 
reinforcement and addictive features in rodents: an overview. Addiction Biology, 
11(1), 2-38. 
Secades-Villa R., Garcia-Rodríguez O., Jin C., Wang S., & Blanco C. (2015). Probability 
and predictors of the cannabis gateway effect: A national study. International 
Journal of Drug Policy, 26(2), 135-143. 
Sharma, P., Murthy, P., & Bharath, M. S. (2012). Chemistry, metabolism, and toxicology 
of cannabis: Clinical implications. Iranian Journal of Psychiatry, 7(4), 149-56. 
Skoglund, G., Nockert, M., & Holst, B. (2013). Viking and early Middle Ages northern 
Scandinavian textiles proven to be made with hemp. Scientific Reports, 3, 2686. 
Solinas, M., Justinova, Z., Goldberg, S. R., & Tanda, G. (2006). Anandamide 
administration alone and after inhibition of fatty acid amide hydrolase (FAAH) 
increases dopamine levels in the nucleus accumbens shell in rats. Journal of 
Neurochemistry, 98(2), 408-419. 
Steketee, J. D., & Kalivas, P. W. (2011). Drug wanting: behavioral sensitization and 
relapse to drug-seeking behavior. Pharmacological Reviews, 63(2), 348-365. 
Stella, N., Schweitzer, P., & Piomelli, D. (1997). A second endogenous cannabinoid that 
modulates long-term potentiation. Nature, 388(6644), 773-778. 
82 
 
Stringer, R. J., & Maggard, S. R. (2016). Reefer Madness to Marijuana legalization: 
media exposure and American attitudes toward marijuana (1975-2012). Journal 
of Drug Issues, 46(4), 428-445. 
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., ... & Waku, K. 
(1995). 2-Arachidonoylgylcerol: A possible endogenous cannabinoid receptor 
ligand in Brain. Biochemical and Biophysical Research Communications, 215(1), 
89-97. 
Sugiura, T., Kondo, S., Sukagawa, A., Tonegawa, T., Nakane, S., Yamashita, A., & 
Waku, K. (1996). Enzymatic synthesis of anandamide, an endogenous 
cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway 
in testis: Involvement of Ca 2+-dependent transacylase and phosphodiesterase 
activities. Biochemical and Biophysical Research Communications, 218(1), 113-
117. 
Sugiura, T., & Waku, K. (2000). 2-Arachidonoylglycerol and the cannabinoid receptors. 
Chemistry and Physics of Lipids, 108(1), 89-106. 
Sulak, D., Saneto, R., & Goldstein, B. (2017). The current status of artisanal cannabis 
for the treatment of epilepsy in the United States. Epilepsy & Behavior, 70(B), 
328-333. 
Sumislawski, J. J., Ramikie, T. S., & Patel, S. (2011). Reversible gating of 
endocannabinoid plasticity in the amygdala by chronic stress: A potential role for 
monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral 
adaptation. Neuropsychopharmacology, 36(13), 2750-2761. 
83 
 
Svíženská, I., Dubový, P., & Šulcová, A. (2008). Cannabinoid receptors 1 and 2 (CB1 
and CB2), their distribution, ligands and functional involvement in nervous 
system structures—a short review. Pharmacology Biochemistry and Behavior, 
90(4), 501-511. 
Tai, S., & Fantegrossi, W. E. (2014). Synthetic cannabinoids: pharmacology, behavioral 
effects, and abuse potential. Current Addiction Reports, 1(2), 129-136. 
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. 
(2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 
and CB2 receptor agonists in vitro. British Journal of Pharmacology, 150(5), 613-
623. 
Thompson, G. R., Rosenkrantz, H., Schaeppi, U. H., & Braude, M. C. (1973). 
Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. 
Toxicology and Applied Pharmacology, 25(3), 363-372. 
Touw, M. (1981). The religious and medicinal uses of Cannabis in China, India and 
Tibet. Journal of Psychoactive Drugs, 13(1), 23-34. 
Tseng, A. H., & Craft, R. M. (2001). Sex differences in antinociceptive and motoric 
effects of cannabinoids. European Journal of Pharmacology, 430(1), 41-47. 
Tsou, K., Brown, S., Sanudo-Pena, M. C., Mackie, K., & Walker, J. M. (1998). 
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central 
nervous system. Neuroscience, 83(2), 393-411. 
84 
 
Ujike, H., Tsuchida, K., Akiyama, K., Fujiwara, Y., & Kuroda, S. (1995). Ontogeny of 
behavioral sensitization to cocaine. Pharmacology Biochemistry and 
Behavior, 50(4), 613-617. 
Valenti, M., Vigano, D., Casico, M. G., Rubino, T., Steardo, L., Parolaro, D., & Di Marzo, 
V. (2004). Differential diurnal variations of anandamide and 2-arachidonoyl-
glycerol levels in rat brain. Cellular and Molecular Life Sciences, 61(7-8), 945-
950. 
Varvel, S. A., Martin, B. R., & Lichtman, A. H. (2007). Lack of behavioral sensitization 
after repeated exposure to THC in mice and comparison to 
methamphetamine. Psychopharmacology, 193(4), 511-519. 
Vergara, D., Bidwell, L. C., Gaudino, R., Torres, A., Du, G., & Ruthenburg, T. C. (2017). 
Compromised external validity: federally produced cannabis does not reflect legal 
markets. Scientific Reports, 7, 46528. 
Verweij, K. J. H., Agrawal, A., Nat, N. O., Creemers, H. E., Huizink, A. C., Martin, N. G., 
& Lynskey, M. T. (2013). A genetic perspective on the proposed inclusion of 
cannabis withdrawal in DSM-5. Psychological Medicine, 43(08), 1713-1722. 
Vezina, P. (1996). D1 dopamine receptor activation is necessary for the induction of 
sensitization by amphetamine in the ventral tegmental area. Journal of 
Neuroscience, 16(7), 2411-2420. 
Vigano, D., Cascio, M. G., Rubino, T., Fezza, F., Vaccani, A., Di Marzo, V., & Parolaro, 
D. (2003). Chronic morphine modulates the contents of the endocannabinoid, 2-
arachidonoyl glycerol, in rat brain. Neuropsychopharmacology, 28(6), 1160. 
85 
 
Viveros, M. P., Llorente, R., Moreno, E., & Marco, E. M. (2005). Behavioural and 
neuroendocrine effects of cannabinoids in critical developmental periods. 
Behavioural Pharmacology, 16(5-6), 353-362. 
Wall, M. E., Sadler, B. M., Brine, D., Taylor, H., & Perez‐Reyes, M. (1983). Metabolism, 
disposition, and kinetics of delta‐9‐tetrahydrocannabinol in men and women. 
Clinical Pharmacology & Therapeutics, 34(3), 352-363. 
Wang, G. S., Roosevelt, G., Le Lait, M. C., Martinez, E. M., Bucher-Bartelson, B., 
Bronstein, A. C., & Heard, K. (2014). Association of unintentional pediatric 
exposures with decriminalization of marijuana in the United States. Annals of 
Emergency Medicine, 63(6), 684-689. 
Weiss, S. R. B., Post, R. M., Pert, A., Woodward, R., & Murman, D. (1989). Role of 
conditioning in cocaine-induced behavioral sensitization. Pharmacology 
Biochemistry, and Behavior, 34, 655-661. 
Werner, C. A. (2001). Medical marijuana and the AIDS crisis. Journal of Cannabis 
Therapeutics, 1(3-4), 17-33. 
Williams, C. M., & Kirkham, T. C. (2002). Observational analysis of feeding induced by 
Δ 9-THC and anandamide. Physiology & Behavior, 76(2), 241-250. 
Zavala, A. R., Nazarian, A., Crawford, C. A., & McDougall, S. A. (2000). Cocaine-
induced behavioral sensitization in the young rat. Psychopharmacology, 151(2-
3), 291-298. 
Zuardi, A. W. (2006). History of cannabis as a medicine: A review. Revista Brasileira de 
Psiquiatría, 28(2), 153-157. 
